AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE

N/A

Manufactured by Kenvue Brands LLC

273 FDA adverse event reports analyzed

Last updated: 2026-04-15

About AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE

AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Kenvue Brands LLC. The most commonly reported adverse reactions for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE include SKIN CANCER, BASAL CELL CARCINOMA, NEOPLASM MALIGNANT, MALIGNANT MELANOMA, RASH. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE.

Top Adverse Reactions

SKIN CANCER32 reports
BASAL CELL CARCINOMA14 reports
NEOPLASM MALIGNANT13 reports
MALIGNANT MELANOMA12 reports
RASH11 reports
BURNS THIRD DEGREE9 reports
RECALLED PRODUCT ADMINISTERED7 reports
SUNBURN7 reports
DRUG INEFFECTIVE6 reports
PRURITUS6 reports
SQUAMOUS CELL CARCINOMA6 reports
APPLICATION SITE BURN5 reports
PRODUCT LOT NUMBER ISSUE5 reports
URTICARIA5 reports
APPLICATION SITE RASH4 reports
BLISTER4 reports
BREAST CANCER4 reports
HYPERSENSITIVITY4 reports
PRODUCT EXPIRATION DATE ISSUE4 reports
RASH PRURITIC4 reports
ADVERSE EVENT3 reports
APPLICATION SITE ERYTHEMA3 reports
APPLICATION SITE PAIN3 reports
APPLICATION SITE SWELLING3 reports
COUGH3 reports
PRODUCT CONTAMINATION CHEMICAL3 reports
SKIN DISCOLOURATION3 reports
SKIN EXFOLIATION3 reports
ACCIDENTAL EXPOSURE TO PRODUCT2 reports
ACUTE MYELOID LEUKAEMIA2 reports
ANGIOEDEMA2 reports
APPLICATION SITE REACTION2 reports
CHEMICAL BURN2 reports
DERMATITIS ATOPIC2 reports
DIZZINESS2 reports
ERYTHEMA2 reports
EXPIRED PRODUCT ADMINISTERED2 reports
HAEMATOLOGICAL MALIGNANCY2 reports
LEUKAEMIA2 reports
PHOTOSENSITIVITY REACTION2 reports
POST INFLAMMATORY PIGMENTATION CHANGE2 reports
PRODUCT QUALITY ISSUE2 reports
RASH ERYTHEMATOUS2 reports
ABDOMINAL DISTENSION1 reports
ABNORMAL WEIGHT GAIN1 reports
ANXIETY1 reports
APPENDIX CANCER1 reports
APPLICATION SITE DRYNESS1 reports
APPLICATION SITE EXFOLIATION1 reports
APPLICATION SITE HYPERSENSITIVITY1 reports
APPLICATION SITE IRRITATION1 reports
APPLICATION SITE PUSTULES1 reports
APPLICATION SITE SCAR1 reports
APPLICATION SITE VESICLES1 reports
ARTHROPOD BITE1 reports
BLADDER CANCER1 reports
BLADDER CANCER STAGE III1 reports
BLOOD BLISTER1 reports
BONE PAIN1 reports
BURNING SENSATION1 reports
CHEST DISCOMFORT1 reports
CONFUSIONAL STATE1 reports
DEATH1 reports
DERMATITIS1 reports
DERMATITIS ALLERGIC1 reports
DERMATITIS CONTACT1 reports
DRUG HYPERSENSITIVITY1 reports
DRY SKIN1 reports
DYSPNOEA1 reports
ECZEMA1 reports
EXPOSURE TO TOXIC AGENT1 reports
EXPOSURE VIA INHALATION1 reports
EYE DISORDER1 reports
EYE SWELLING1 reports
FURUNCLE1 reports
GAIT DISTURBANCE1 reports
HAEMORRHAGE1 reports
HEADACHE1 reports
HYPOAESTHESIA ORAL1 reports
ILL DEFINED DISORDER1 reports
INCORRECT PRODUCT ADMINISTRATION DURATION1 reports
INFLUENZA LIKE ILLNESS1 reports
LACRIMATION INCREASED1 reports
LIP BLISTER1 reports
MELANOCYTIC NAEVUS1 reports
MILIARIA1 reports
MOLLUSCUM CONTAGIOSUM1 reports
MONOCLONAL GAMMOPATHY1 reports
NASAL CONGESTION1 reports
NON HODGKIN^S LYMPHOMA1 reports
OROPHARYNGEAL PAIN1 reports
OTITIS MEDIA ACUTE1 reports
PAPULE1 reports
PARAESTHESIA ORAL1 reports
PLASMA CELL MYELOMA1 reports
PRECANCEROUS CONDITION1 reports
PRECANCEROUS SKIN LESION1 reports
PRODUCT ADMINISTRATION ERROR1 reports
PRODUCT CONTAINER ISSUE1 reports
PRODUCT CONTAMINATION1 reports

Report Outcomes

Out of 155 classified reports for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE:

Serious 85.2%Non-Serious 14.8%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Female68 (61.3%)
Male43 (38.7%)

Reports by Age

Age 326 reports
Age 63 reports
Age 383 reports
Age 413 reports
Age 603 reports
Age 72 reports
Age 212 reports
Age 242 reports
Age 332 reports
Age 342 reports
Age 502 reports
Age 552 reports
Age 592 reports
Age 622 reports
Age 662 reports
Age 11 reports
Age 91 reports
Age 111 reports
Age 141 reports
Age 151 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE?

This profile reflects 273 FDA FAERS reports that mention AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE?

Frequently reported terms in FAERS include SKIN CANCER, BASAL CELL CARCINOMA, NEOPLASM MALIGNANT, MALIGNANT MELANOMA, RASH, BURNS THIRD DEGREE. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE?

Labeling and FAERS entries often list Kenvue Brands LLC in connection with AVOBENZONE, HOMOSALATE, OCTISALATE, OCTOCRYLENE, AND OXYBENZONE. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.